NCT04449874: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- State
- Under way
- Phase
- Phase 1
- People
- 498 planned
- Started
- 29 Jul 2020
- Primary completion
- 31 Dec 2027
- Arms
- Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)
- Results
- None posted
- 29 Jun 2020: Trial registered
- 29 Jul 2020: Trial started